UK Medicines Information
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Information type:
Randomised controlled trials
Source:
The Lancet Oncology
Specialities:
Cancers
Summary
In this study (n=602), trastuzumab emtansine was associated with prolonged PFS when compared to physician’s choice of therapy in women with progressive pretreated HER2+ advanced breast cancer (median 6.2 vs. 3.3 months; p<0.0001). More mature overall survival data are awaited.
UKMi comment
A Comment article discussing the results of study is available at the link below.
Related links:
Comment